Axelar Announces Final Data from Phase II Study with AXL1717 in Lung Cancer

News   Dec 27, 2013

 
Axelar Announces Final Data from Phase II Study with AXL1717 in Lung Cancer
 
 
 

RELATED ARTICLES

UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPO

News

MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).

READ MORE

A Carcinogen at the Gym

News

Gyms are places people go to get healthier. But nearly half the gyms in the U.S. contain a potentially addictive carcinogen - tanning beds, report UConn researchers.

READ MORE

A Mechanism of Drug Resistance in Breast & Ovarian Cancer

News

Researchers have discovered the molecular means by which some cancers caused by errors in the gene BRCA1 evade treatment by drugs custom-tailored to kill them.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy